Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Deloitte
Johnson and Johnson
Colorcon
Farmers Insurance
Harvard Business School
McKesson
Cerilliant
AstraZeneca

Generated: May 22, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021712

« Back to Dashboard

NDA 021712 describes FLUXID, which is a drug marketed by Ucb Inc and is included in one NDA. There are two patents protecting this drug. Additional details are available on the FLUXID profile page.

The generic ingredient in FLUXID is famotidine. There are eighteen drug master file entries for this compound. One hundred and seventeen suppliers are listed for this compound. Additional details are available on the famotidine profile page.
Summary for 021712
Tradename:FLUXID
Applicant:Ucb Inc
Ingredient:famotidine
Patents:2
Therapeutic Class:Gastrointestinal Agents
Formulation / Manufacturing:see details
Medical Subject Heading (MeSH) Categories for 021712

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:TABLET, ORALLY DISINTEGRATING;ORALStrength20MG
Approval Date:Sep 24, 2004TE:RLD:No
Patent:➤ Sign UpPatent Expiration:Apr 9, 2018Product Flag?YSubstance Flag?Delist Request?
Patent:➤ Sign UpPatent Expiration:Apr 9, 2018Product Flag?YSubstance Flag?Delist Request?

Profile for product number 002

Active Rx/OTC/Discontinued:DISCNDosage:TABLET, ORALLY DISINTEGRATING;ORALStrength40MG
Approval Date:Sep 24, 2004TE:RLD:No
Patent:➤ Sign UpPatent Expiration:Apr 9, 2018Product Flag?YSubstance Flag?Delist Request?

Expired US Patents for NDA 021712

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ucb Inc FLUXID famotidine TABLET, ORALLY DISINTEGRATING;ORAL 021712-002 Sep 24, 2004 ➤ Sign Up ➤ Sign Up
Ucb Inc FLUXID famotidine TABLET, ORALLY DISINTEGRATING;ORAL 021712-001 Sep 24, 2004 ➤ Sign Up ➤ Sign Up
Ucb Inc FLUXID famotidine TABLET, ORALLY DISINTEGRATING;ORAL 021712-001 Sep 24, 2004 ➤ Sign Up ➤ Sign Up
Ucb Inc FLUXID famotidine TABLET, ORALLY DISINTEGRATING;ORAL 021712-002 Sep 24, 2004 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Accenture
Deloitte
Cerilliant
US Army
Daiichi Sankyo
Teva
Boehringer Ingelheim
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.